The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Relative risk of cardiovascular disease among people living with HIV : a systematic review and meta‐analysis
Open accessAbstract
Objectives: The aim of this study was to estimate the relative risk of cardiovascular disease ( CVD ) among people living with HIV ( PLHIV ) compared with the HIV ‐uninfected population. Methods: We conducted a systematic review and meta‐analysis of studies from the peer‐reviewed literature. We searched the M edline database for relevant journal articles published before A ugust 2010. Eligible studies were observational and randomized controlled trials, reporting CVD , defined as myocardial infarction ( MI ), ischaemic heart disease, cardiovascular and cerebrovascular events or coronary heart disease among HIV ‐positive adults. Pooled relative risks were calculated for various groupings, including different classes of antiretroviral therapy ( ART ). Results: The relative risk of CVD was 1.61 [95% confidence interval ( CI ) 1.43–1.81] among PLHIV without ART compared with HIV ‐uninfected people. The relative risk of CVD was 2.00 (95% CI 1.70–2.37) among PLHIV on ART compared with HIV ‐uninfected people and 1.52 (95% CI 1.35–1.70) compared with treatment‐naïve PLHIV . We estimate the relative risk of CVD associated with protease inhibitor ( PI )‐, nucleoside reverse transcriptase inhibitor‐ and nonnucleoside reverse transcriptase inhibitor‐based ART to be 1.11 (95% CI 1.05–1.17), 1.05 (95% CI 1.01–1.10) and 1.04 (95% CI 0.99–1.09) per year of exposure, respectively. Not all ART was associated with increased risk; specifically, lopinavir/ritonavir and abacavir were associated with the greater risk and the relative risk of MI for PI ‐based versus non‐ PI ‐based ART was 1.41 (95% CI 1.20–1.65). Conclusion: PLHIV are at increased risk of cardiovascular disease. Although effective in prolonging survival, ART (in particular PI ‐based regimens) is related to further increased risk of CVD events among people at highest initial absolute risk of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HIV patients have been found to have a higher risk of cardiovascular events, which was even higher in patients treated with protease inhibitors (Friis‐Moller et al, 2007; Islam et al, 2012; Shah et al, 2018).”
From The struggle of a good friend getting old: cellular senescence in viral responses and therapy (2021) · cites this paper as Islam et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393
Research works printed but not linked: 6
- UNAIDS, 2010, Global report: UNAIDS report on the global AIDS epidemic 2010
- BedimoR WestfallA DrechslerH TebasP editors.Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era.5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town South Africa 2009[Abstract MOAB202].
- BenitoR PinillaJ LabargaPet al. editors.Comparison of cardiovascular risk factors between HIV‐infected patients and non‐infected general population.The 14th International AIDS Conference. Barcelona Spain July2002[Abstract B10290].
- DurandM SheehyO BarilJ‐G LelorierJ TremblayC editors.Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID).5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town South Africa 2009[Abstract TUPEB175].
- HolmbergSD MoormanAC TongTCet al. editors.Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV‐infected patients.The 14th International AIDS Conference. Barcelona Spain July2002[Abstract TuPeB4494].
- KleinD HurleyL SilverbergM HorbergM QuesenberryC SidneyS editors.Surveillance Data for Myocardial Infarction Hospitalizations among HIV+ and HIV‐ Northern Californians: 1994–2006.14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 807].
Cited by
Sorted by citations
Items 401–432 of 432
Musarurwa, H. T., Brix, B., Kessler, H. H., Roessler, A., Sewani-Rusike, C. R., Nkeh-Chungag, B. N., & Goswami, N. (2023) · Research Square · doi:10.21203/rs.3.rs-2441349/v1
Pan, S., Fu, H., Ai, Z.-Q., Li, C., & Bai, J. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231174600
“52 times higher risk of CVD than unaffected individuals, and the risk factors of CVD vary based on the treatment regime.(3) The number of people with AIDS-related CVD(4) and the proportion of deaths(5) has gradually increased worldwide over the past 20 years.”
BackgroundWorld AIDS Day 2023: understanding the interconnected challenges of HIV and cardiovascular disease
Neubeck, L. (2023) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2023.0091
van der Post, J., Guerra, T. E. J., den Hof, M. V., Vaz, F. M., Pajkrt, D., & van Genderen, J. G. (2024) · Viruses · doi:10.3390/v16040580
“Despite adequate viral suppression with cART, long-term complications such as increased cardiovascular risk (CVD) and metabolic syndrome (MetS) are still eminent in HIV-infected individuals [2,3].”
BackgroundChaubey, M., Chakravarty, J., Gupta, R., Jethwani, P., Puri, R., & Sundar, S. (2024) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_29_24
Lipidmanagement bei Patienten mit HIV
Vogt, A. (2024) · CardioVasc · doi:10.1007/s15027-024-3610-3
HIV and risk of hypertension: a two-sample Mendelian randomization study
Zhu, R.-W., Guo, H., Niu, L.-N., Deng, M., Li, X.-F., & Jing, L. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10182-w
Coronary artery disease and human immunodeficiency virus
Sharma, T., Sharma, B., Chaudhary, R., Faraday, N. R., & Goldsweig, A. M. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103101
Donkor, M., Massey, I. Y., Amponsah, S. K., Amo-kodieh, P., Dormechele, W., Apenkwa, J., & Nunfam, V. F. (2025) · Research Square · doi:10.21203/rs.3.rs-6693996/v1
Trisolini, P., Cammarota, S., Citarella, A., Fogliasecca, M., Alicchio, V., Antonacci, S., Giannini, R., Lombardi, R., Piccoli, M., Pomarico, F., et al. (2025) · Viruses · doi:10.3390/v17091212
“When compared to people without HIV, PWH have about a twofold higher risk of developing atherosclerotic cardiovascular disease (ASCVD), and their age at incident ASCVD diagnosis is about a decade younger [12,13].”
Hsue, P. Y., Behrens, G. M. N., Xu, Z. J., Zhao, Y., C’mar, J., Lahoulou, R., Campo, R. E., & Plank, R. M. (2025) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003778
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios and Cardiovascular Risk in HIVPreprint
Tobin, J. N., Tian, Y., Arora, M. K., Ahmed, T., Siyanbola, M. A., González, A. M. T., VAUGHAN, R. D., Fiscella, K. A., & Evering, T. H. (2025) · medRxiv · doi:10.1101/2025.11.21.25340769
Cardiovascular disease in people living with HIV in Malaysia: A competing risks cohort analysis
Teh, H. S., Tay, K. H., Lim, Y. M. F., Yang, S. L., Lee, J. L., Anand, S., Sim, B. L. H., & Hwong, W. Y. (2025) · HIV Medicine · doi:10.1111/hiv.70145
Cardiovascular risk and prevention among men living with HIV in Islamabad: a qualitative study
Asghar, N., & Qureshi, A. (2025) · Journal of HIV/AIDS & Social Services · doi:10.1080/15381501.2025.2598648
Protein adducts from the anti-HIV drug abacavir – possible biomarkers of drug toxicity
Grilo, N. M. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Ottaru, T. A., Wood, C. V., Butt, Z. A., Hawkins, C., Hirschhorn, L. R., Karoli, P., Shayo, E. H., Metta, E. O., Chillo, P., Siril, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25200669
Ottaru, T. A., Wood, C. V., Butt, Z. A., Hawkins, C., Hirschhorn, L. R., Karoli, P., Shayo, E. H., Metta, E. O., Chillo, P., Siril, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26679311
Maritati, M., Trentini, A., Zanotta, N., Comar, M., Bellini, T., Sighinolfi, L., & Contini, C. (2020) · Figshare · doi:10.6084/m9.figshare.13093688
Ottaru, T. A., Wood, C. V., Butt, Z. A., Hawkins, C., Hirschhorn, L. R., Karoli, P., Shayo, E. H., Metta, E. O., Chillo, P., Siril, H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25200732
Mendoza‐Marí, Y., & Agrawal, D. K. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_27
The Impact of Natural and Synthetic Antioxidants in Disease Development in Humans
Priya, S. D., Subhashini, S., Ramesh, R., & Anandaraj, L. (2026) · Springer eBooks · doi:10.1007/978-981-96-9670-3_4
Barcellini, L., Sauer, S. M., Romo, M. L., Mitnick, C. D., Huerga, H., Khan, U., Hewison, C., Rich, M., Franke, M. F., & Khan, P. Y. (2026) · IJTLD OPEN · doi:10.5588/ijtldopen.26.0076
“20,21 We proposed that HIV infection worsens MDR/RR-TB treatment outcomes both directly by compromising the immune response 22 and indirectly, by delaying diagnosis and leading to greater disease severity and poorer general condition.”
Okwir, M., Okello, E., Link, A., Akullo, I., Odongo, P., Omech, B., Kiweewa, F., Liu, Y., Meya, D., Bohjanen, P. R., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12895-6 · Cited by 1
“Traditional cardiovascular disease risk factors like smoking, combined with HIV infection and prolonged antiretroviral therapy further exacerbate this risk [21, 31, 32].”
Figueira, F. J. A., Tavares, M. D. S. F., Andreucci, C. B., Souto, B. G. A., & Osório, N. S. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03091-3
Schönenberger, C., Speich, B., Zehnder, E. R., Haerry, D. H.-U., Cart-Richter, E., Jackson‐Perry, D., Hutter, A., Aggeler, S., Steinmann, J., Chaudron, S. E., et al. (2026) · Trials · doi:10.1186/s13063-026-09622-6
“Two meta-analyses suggested a doubled overall risk for cardiovascular disease in this population compared to the general population [2, 8, 9].”
Fu, F., Spencer, D. I. R., Winston, A., & Sabin, C. A. (2026) · Future Virology · doi:10.1080/17460794.2026.2667108
Sex differences in cardiovascular disease in people with and without HIV
Shi, F., Xia, H., Weissman, S., Li, X., & Yang, X. (2026) · AIDS · doi:10.1097/qad.0000000000004567
Krieg, S., Krieg, A. H., & Kostev, K. (2026) · European journal of medical research · doi:10.1186/s40001-026-04678-1
“Among these chronic conditions, cardiovascular diseases (CVD) are now recognized as major contributors to morbidity and mortality in PLHIV [1, 7–10].”
Bellinati, P. Q., Lozovoy, M. A. B., Ahrens, T. M., Gasparetto, P. F., dos Santos, E., de Araujo, D. N. F., Alvarenga, T. M., Sakamoto, L. M., Santos, D. F. P., Fajardo, J. Z., et al. (2026) · Human Immunology · doi:10.1016/j.humimm.2026.111804
Masoza, T. S., Andy, C., Willkens, M. A., Kibona, S., Bundschuh, E., Peck, R. N., Kalluvya, S. E., & Reif, L. K. (2026) · HIV Research & Clinical Practice · doi:10.1080/25787489.2026.2725472
Renzaho, A. M. N. (2026) · International Journal of Migration Health and Social Care · doi:10.1108/ijmhsc-04-2025-0048
Metadata
- Authors
- Islam, F., Wu, J., Jansson, J., & Wilson, D.
- Affiliations
- The Kirby Institute Faculty of Medicine University of New South Wales Sydney NSW Australia
- UNSW Sydney (AU)
- Corresponding author
- Wilson, DP
- ORCID
- Venue
- HIV Medicine
- Publisher
- Wiley
- Published
- 2012-03-14
- Volume
- 13
- Issue
- 8
- Pages
- 453-468
- ISSN
- 1464-2662 (ISSN-L)
- 1468-1293
- OpenAlex
- W1677033108
- Cited by
- 432
- References
- 40
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 28 · 2023: 19 · 2022: 31 · 2021: 39 · 2020: 42 · 2019: 28 · 2018: 44 · 2017: 34 · 2016: 40 · 2015: 29 · 2014: 27 · 2013: 26 · 2012: 15
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- HIV Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Australian Government
- Medical Research Council
- Australian Research Council (DP1093026, FT0991990)
- National Health and Medical Research Council (630495)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- cardiovascular disease, people living with HIV, antiretroviral therapy, protease inhibitors, myocardial infarction, ischemic heart disease, coronary artery disease, cerebrovascular events, lopinavir/ritonavir, abacavir, cardiovascular risk
- MeSH terms
- Adult, Cardiovascular Diseases, Humans, Protease Inhibitors, Risk Factors, HIV Infections, Incidence, Reverse Transcriptase Inhibitors, Anti-Retroviral Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
